|Home | About | Journals | Submit | Contact Us | Français|
Cancer prevention and treatment strategies are improving population health. Current and future progress is clearly dependent on the translation of basic understanding of cancer to patient care. Cancer clinicians can be justifiably proud of the role they assume in delivering better treatment to patients. It is equally fair to say that there is far more to be done, and future improvements in cancer care will have to emerge in a rapidly changing financial environment. The cost of health care (including cancer care) in the United States is growing more rapidly than the overall economy and currently consumes 16% of the gross domestic product.1
The rising cost of cancer care affects many stakeholders who play roles in a complex health care system. Our patients are the most vulnerable, because they often experience uneven insurance coverage leading to financial strain or even ruin. Other key groups include pharmaceutical and device manufacturers that bring innovation to the clinic and ultimately must pass on research, development, and marketing costs to the consumer; providers of cancer care, who dispense expensive drugs and diagnostics; and the insurance industry, faced with the increasing cost of care and high demand for the newest technologies. Increasingly, the economic burden of health care in general—and high-quality cancer care in particular—will be less and less affordable for many Americans unless steps are taken to curb dangerous trends in health care spending.
The ASCO Cost of Care Task Force has developed a guidance statement on the cost of cancer care, stressing:
Read the full statement in Journal of Clinical Oncology.
Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology Guidance Statement: The cost of cancer care. J Clin Oncol doi.10.1200/JCO.2009.23.1183 [epub ahead of print on July 6, 2009]
ASCO is committed to improving cancer prevention, diagnosis, and treatment and eliminating disparities in cancer care through support of evidence-based and cost-effective practices. To address this goal, ASCO established the Cost of Care Task Force, which has considered many of the implications of rising costs and recently developed a guidance statement on the cost of cancer care.2 The guidance statement provides a concise overview of the economic issues facing stakeholders in the cancer community. It also recommends the following steps be taken to address immediate needs:
Cancer care in the United States is delivered in the setting of a health care system that is not integrated. As a result, the components of the system (ie, providers, insurers, and pharmaceutical and device manufacturers) do not function in coordinated ways that would facilitate the greatest benefit for the largest number of people at the lowest cost. Because improving the well-being of cancer patients and facilitating the highest levels of practice and professionalism among cancer clinicians are central to its mission, ASCO is committed to contributing to the national discussion on how best to provide high-quality cancer care to all patients with and at risk for cancer. Doing so will require a clear understanding of the factors that drive cancer care costs as well as potential modifications to the current system to ensure that these goals are met. Research is needed in patient-physician communication to optimize information exchange and preference-sensitive decision making. In addition, we need to learn more about the comparative effectiveness of oncology therapies (eg, drugs, radiation, and surgical approaches) and diagnostics. Ultimately, we need to better understand the value of particular cancer treatments and how different stakeholders approach such judgments. These data are needed to inform the decisions of individual patients, their physicians, and society at large.
With the publication of its guidance statement, the ASCO Task Force on the Cost of Cancer Care is poised to probe these issues more deeply by understanding the drivers of increasing costs, their impact, and approaches to modulating them in an effort to ensure continued progress against cancer and universal access to high-quality care.
Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.
Employment or Leadership Position: None Consultant or Advisory Role: Neal J. Meropol, Saladax (C), sanofi-aventis (C), Helsinn (C), Pfizer (C), Genomic Health (C), Veridex (C), Genentech (C), Amgen (C), AstraZeneca (C) Stock Ownership: Neal J. Meropol, Saladax Honoraria: Neal J. Meropol, Biogen Idec (C) Research Funding: None Expert Testimony: None Other Remuneration: None